Clinical Trial Update: A Combination Clinical Study of PLX3397 and Pembrolizumab To Treat Advanced Melanoma and Other Solid Tumors [Phase 1, Phase 2]

View source ↗

Summary

A phase 1/2 study evaluating PLX3397 in combination with pembrolizumab in advanced melanoma and other solid tumors was terminated; results were posted in 2019.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastrointestinal Stromal Tumor
• Melanoma
• Non-small Cell Lung Cancer
• Ovarian Cancer
• Squamous Cell Carcinoma of the Head and Neck

Drugs mentioned

• PLX3397 (PLX3397)
• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: Daiichi Sankyo | Conditions: Melanoma, Non-small Cell Lung Cancer | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2019-10-09